Lewin Group, Falls Church, VA, USA.
J Clin Hypertens (Greenwich). 2012 Jun;14(6):388-95. doi: 10.1111/j.1751-7176.2012.00656.x. Epub 2012 May 7.
As a result of the Food and Drug Administration (FDA) Modernization Act and the Best Pharmaceuticals for Children Act, the number of medications with FDA-approved pediatric labeling has increased. To assess the success of these initiatives, we examined whether antihypertensive drugs used by children with hypertension in 2008 had FDA-approved pediatric labeling and indications. Using a nationwide commercial insurer database, 2915 children with primary (n=2607) and secondary (n=308) hypertension were identified. Drug user rate and days of supply were calculated from pharmacy claims. Drugs were categorized based on pediatric labeling and indication and whether they were recommended for pediatric use. Antihypertensive drugs were used by 889 (34%) children with primary hypertension and 200 children (65%) with secondary hypertension. User rates were 44.3% in hypertensive children younger than 6 years, 30.9% in those 6 years to older than 12 years, and 38.1% in those 12 years to older than 18 years. Seven percent of drugs were neither labeled for pediatric use nor considered recommended for use in children. In children younger than 6 years, 29% of drugs used were not indicated for use in that age group. Despite recent legislative initiatives, many drugs used by hypertensive children still lack pediatric labeling. Additional efforts are needed to close the gap between the availability of drugs that are labeled and indicated for pediatric use and actual drug usage in children.
由于食品和药物管理局(FDA)现代化法案和最佳儿科药物法案的实施,具有 FDA 批准的儿科标签的药物数量有所增加。为了评估这些举措的成功,我们研究了 2008 年患有高血压的儿童使用的降压药物是否具有 FDA 批准的儿科标签和适应证。我们使用全国性商业保险公司数据库,确定了 2915 名患有原发性高血压(n=2607)和继发性高血压(n=308)的儿童。根据药房报销计算药物使用率和供应天数。药物根据儿科标签和适应证以及是否推荐用于儿科使用进行分类。降压药物用于 889 名(34%)原发性高血压儿童和 200 名(65%)继发性高血压儿童。在年龄小于 6 岁的高血压儿童中,使用率为 44.3%,在年龄为 6 岁至 12 岁以上的儿童中为 30.9%,在年龄为 12 岁至 18 岁以上的儿童中为 38.1%。有 7%的药物既未标签用于儿科使用,也未被认为可在儿童中使用。在年龄小于 6 岁的儿童中,29%使用的药物不适用于该年龄组。尽管最近有立法举措,但高血压儿童使用的许多药物仍缺乏儿科标签。需要进一步努力,缩小标签和适应证为儿科使用的药物与儿童实际用药之间的差距。